Fenofibrate

Canertinib (CI-1033) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4.An irreversible pan-erbB tyrosine kinase inhibitor.

Canertinib (CI-1033) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4.An irreversible pan-erbB tyrosine kinase inhibitor.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

Application Fenofibrate has been used: to study its effect on plasma lipids, liver phenotype and gene expression to study its impact on endothelium-dependent vasodilatation of thoracic aorta to administer to NASH knock-in mice along with a high fat

Application Fenofibrate has been used: to study its effect on plasma lipids, liver phenotype and gene expression to study its impact on endothelium-dependent vasodilatation of thoracic aorta to administer to NASH knock-in mice along with a high fat

Application Fenofibrate has been used: to study its effect on plasma lipids, liver phenotype and gene expression to study its impact on endothelium-dependent vasodilatation of thoracic aorta to administer to NASH knock-in mice along with a high fat

General description Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Fenofibrate

A hypolipidemic PPARα agonist.Fenofibrate has been used:• to study its effect on plasma lipids, liver phenotype and gene expression；• to study its impact on endothelium-dependent vasodilatation of thoracic aorta；• to administer to NASH knock-in mice

A hypolipidemic PPARα agonist.Fenofibrate has been used:• to study its effect on plasma lipids, liver phenotype and gene expression；• to study its impact on endothelium-dependent vasodilatation of thoracic aorta；• to administer to NASH knock-in mice

A hypolipidemic PPARα agonist.Fenofibrate has been used:• to study its effect on plasma lipids, liver phenotype and gene expression；• to study its impact on endothelium-dependent vasodilatation of thoracic aorta；• to administer to NASH knock-in mice

A hypolipidemic PPARα agonist.Fenofibrate has been used:• to study its effect on plasma lipids, liver phenotype and gene expression；• to study its impact on endothelium-dependent vasodilatation of thoracic aorta；• to administer to NASH knock-in mice